KDR and neoplasm: The activities of genes in tumour vessels (such as VEGFR2 and VEGFR3 (also called FLT4)) and tumour cells can be suppressed by the multikinase inhibitor, sorafenib, and sorafenib exerts antiangiogenic and antiproliferative effects in advanced THCA [31].